MetaVia Announces Updates on Obesity and Metabolic Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 04 2026
0mins
Source: PRnewswire
- Management Presentation: MetaVia Inc. will present updates on its novel obesity and metabolic therapies at the Emerging Growth Conference on June 11, 2026, at 3:25 PM ET, featuring insights from CEO Hyung Heon Kim and CFO Marshall H. Woodworth, showcasing the company's innovative advancements in cardiometabolic diseases.
- DA-1726 Clinical Trial: In a Phase 1 multiple ascending dose trial for obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction, functioning as a dual agonist for GLP-1 and GCGR, potentially outperforming selective GLP-1 receptor agonists like semaglutide in weight management.
- Positive Effects of Vanoglipel: As a novel GPR119 agonist, vanoglipel showed positive effects on liver inflammation, lipid metabolism, and glucose metabolism in preclinical studies, reducing hepatic steatosis, inflammation, and fibrosis, while also demonstrating direct hepatic action in a Phase 2a clinical study.
- Virtual Conference Logistics: Attendees can submit questions in advance, and a Q&A session will follow the presentation, while those unable to join live can access an archived webcast on MetaVia's events page, enhancing investor engagement and transparency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTVA
Wall Street analysts forecast MTVA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.710
Low
40.00
Averages
47.50
High
55.00
Current: 1.710
Low
40.00
Averages
47.50
High
55.00
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MetaVia to Participate in Life Sciences Investor Forum
- Executive Forum Participation: MetaVia's CEO Hyung Heon Kim will participate in the Life Sciences Virtual Investor Forum on June 24, 2026, showcasing the company's innovative pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance company visibility.
- Real-Time Interaction Opportunity: The forum will feature a live Q&A session, allowing investors to directly engage with the management team, thereby strengthening investor confidence in the company's future developments through enhanced interaction.
- New Drug Development Progress: MetaVia's DA-1726 has demonstrated best-in-class potential for weight loss in obesity treatment, showing promising results in clinical trials for glucose control and waist reduction, which could provide a significant competitive advantage in the market.
- Promising Drug Candidate: Vanoglipel, as a potential first-in-class drug, has shown direct hepatic action and metabolic improvement in clinical studies, and if successfully launched, it could open new revenue streams for the company and elevate its market position.
See More
MetaVia to Participate in Life Sciences Investor Forum
- Executive Forum Participation: MetaVia's CEO Hyung Heon Kim will participate in the Life Sciences Virtual Investor Forum on June 24, 2026, showcasing the company's innovative pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance the company's visibility.
- Real-Time Interaction: The forum will feature a live Q&A session, allowing investors to directly engage with the management team, thereby strengthening investor confidence in the company's future prospects through enhanced interaction.
- New Drug Development Progress: MetaVia's DA-1726 has demonstrated best-in-class potential for weight loss in Phase 1 trials for obesity treatment, potentially outperforming existing GLP-1 receptor agonists, which could significantly enhance the company's competitive position in the biotechnology sector if successful.
- Potential First-in-Class Drug: Vanoglipel, targeting GPR119, has shown positive metabolic effects on glucose and lipid control in preclinical studies, and if validated in subsequent clinical trials, it could open new market opportunities for the company.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Market Opportunities: Biotech companies are experiencing significant pre-market activity on Tuesday, driven by plans for market launches, acquisitions, financing deals, and AI training program launches, indicating potential investment opportunities.
- Notable Gains: Regentis Biomaterials Ltd. (RGNT) saw its stock price surge by 124% to $2.91, reflecting strong market confidence in its future growth and likely attracting more investor interest.
- Significant Losses: Park Ha Biological Technology Co., Ltd. (BYAH) experienced a 39% decline in its stock price to $1.61, indicating market concerns about its business outlook, which may lead investors to reassess their investment strategies.
- Increased Volatility: The price volatility among biotech stocks is heightened, particularly in the context of acquisitions and financing deals, prompting investors to closely monitor market dynamics to seize potential investment opportunities and risks.
See More
MetaVia's DA-1726 Shows Significant Weight Loss Results
- Clinical Trial Results: At the ADA 2026 conference, MetaVia presented that the 48 mg cohort of DA-1726 achieved up to 9.1% mean body weight reduction at Day 54 without evidence of plateau, indicating the drug's potential in obesity treatment and possibly enhancing future market acceptance.
- Safety and Tolerability: DA-1726 demonstrated good tolerability in the 48 mg cohort, with primarily mild-to-moderate gastrointestinal adverse events and no serious adverse events, laying a solid foundation for its further clinical development and boosting investor confidence.
- Combination Therapy Effects: The combination of vanoglipel with resmetirom showed a 23.6% weight reduction in mouse models, along with significant improvements in liver fat and inflammation markers, indicating its potential therapeutic value in metabolic diseases and possibly opening new market opportunities for MetaVia.
- Future Development Plans: MetaVia plans to release results from higher-dose DA-1726 clinical trials in Q4 2026, continuing to advance its research in obesity and metabolic diseases, demonstrating the company's long-term commitment and confidence in its product pipeline.
See More
MetaVia's DA-1726 Shows Significant Weight Loss Results
- Clinical Trial Results: At the ADA 2026 conference, MetaVia presented new Phase 1 results for DA-1726, achieving up to 9.1% weight loss at the 48 mg dose over 54 days without evidence of a plateau, indicating its potential in obesity treatment.
- Safety and Tolerability: DA-1726 demonstrated good tolerability in the 48 mg cohort, with primarily mild-to-moderate gastrointestinal adverse events and no serious adverse events, highlighting its safety profile for clinical use.
- Combination Therapy Effects: The combination of vanoglipel and resmetirom showed synergistic hepatoprotective and weight-loss effects in mouse models, achieving a 23.6% weight reduction and significantly improving liver fat and inflammation markers, supporting its potential in MASH treatment.
- Metabolic Improvements: When combined with metformin, vanoglipel reduced non-fasting glucose by 28.7% and body weight by 16.3%, demonstrating its advantages in type 2 diabetes treatment and further supporting its potential as a therapeutic combination strategy.
See More
MetaVia Announces Updates on Obesity and Metabolic Therapies
- Management Presentation: MetaVia Inc. will present updates on its novel obesity and metabolic therapies at the Emerging Growth Conference on June 11, 2026, at 3:25 PM ET, featuring insights from CEO Hyung Heon Kim and CFO Marshall H. Woodworth, showcasing the company's innovative advancements in cardiometabolic diseases.
- DA-1726 Clinical Trial: In a Phase 1 multiple ascending dose trial for obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction, functioning as a dual agonist for GLP-1 and GCGR, potentially outperforming selective GLP-1 receptor agonists like semaglutide in weight management.
- Positive Effects of Vanoglipel: As a novel GPR119 agonist, vanoglipel showed positive effects on liver inflammation, lipid metabolism, and glucose metabolism in preclinical studies, reducing hepatic steatosis, inflammation, and fibrosis, while also demonstrating direct hepatic action in a Phase 2a clinical study.
- Virtual Conference Logistics: Attendees can submit questions in advance, and a Q&A session will follow the presentation, while those unable to join live can access an archived webcast on MetaVia's events page, enhancing investor engagement and transparency.
See More
MetaVia to Participate in Life Sciences Investor Forum
- Executive Forum Participation: MetaVia's CEO Hyung Heon Kim will participate in the Life Sciences Virtual Investor Forum on June 24, 2026, showcasing the company's innovative pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance company visibility.
- Real-Time Interaction Opportunity: The forum will feature a live Q&A session, allowing investors to directly engage with the management team, thereby strengthening investor confidence in the company's future developments through enhanced interaction.
- New Drug Development Progress: MetaVia's DA-1726 has demonstrated best-in-class potential for weight loss in obesity treatment, showing promising results in clinical trials for glucose control and waist reduction, which could provide a significant competitive advantage in the market.
- Promising Drug Candidate: Vanoglipel, as a potential first-in-class drug, has shown direct hepatic action and metabolic improvement in clinical studies, and if successfully launched, it could open new revenue streams for the company and elevate its market position.
See More
MetaVia to Participate in Life Sciences Investor Forum
- Executive Forum Participation: MetaVia's CEO Hyung Heon Kim will participate in the Life Sciences Virtual Investor Forum on June 24, 2026, showcasing the company's innovative pipeline in obesity and metabolic therapies, which is expected to attract investor interest and enhance the company's visibility.
- Real-Time Interaction: The forum will feature a live Q&A session, allowing investors to directly engage with the management team, thereby strengthening investor confidence in the company's future prospects through enhanced interaction.
- New Drug Development Progress: MetaVia's DA-1726 has demonstrated best-in-class potential for weight loss in Phase 1 trials for obesity treatment, potentially outperforming existing GLP-1 receptor agonists, which could significantly enhance the company's competitive position in the biotechnology sector if successful.
- Potential First-in-Class Drug: Vanoglipel, targeting GPR119, has shown positive metabolic effects on glucose and lipid control in preclinical studies, and if validated in subsequent clinical trials, it could open new market opportunities for the company.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Market Opportunities: Biotech companies are experiencing significant pre-market activity on Tuesday, driven by plans for market launches, acquisitions, financing deals, and AI training program launches, indicating potential investment opportunities.
- Notable Gains: Regentis Biomaterials Ltd. (RGNT) saw its stock price surge by 124% to $2.91, reflecting strong market confidence in its future growth and likely attracting more investor interest.
- Significant Losses: Park Ha Biological Technology Co., Ltd. (BYAH) experienced a 39% decline in its stock price to $1.61, indicating market concerns about its business outlook, which may lead investors to reassess their investment strategies.
- Increased Volatility: The price volatility among biotech stocks is heightened, particularly in the context of acquisitions and financing deals, prompting investors to closely monitor market dynamics to seize potential investment opportunities and risks.
See More
MetaVia's DA-1726 Shows Significant Weight Loss Results
- Clinical Trial Results: At the ADA 2026 conference, MetaVia presented that the 48 mg cohort of DA-1726 achieved up to 9.1% mean body weight reduction at Day 54 without evidence of plateau, indicating the drug's potential in obesity treatment and possibly enhancing future market acceptance.
- Safety and Tolerability: DA-1726 demonstrated good tolerability in the 48 mg cohort, with primarily mild-to-moderate gastrointestinal adverse events and no serious adverse events, laying a solid foundation for its further clinical development and boosting investor confidence.
- Combination Therapy Effects: The combination of vanoglipel with resmetirom showed a 23.6% weight reduction in mouse models, along with significant improvements in liver fat and inflammation markers, indicating its potential therapeutic value in metabolic diseases and possibly opening new market opportunities for MetaVia.
- Future Development Plans: MetaVia plans to release results from higher-dose DA-1726 clinical trials in Q4 2026, continuing to advance its research in obesity and metabolic diseases, demonstrating the company's long-term commitment and confidence in its product pipeline.
See More
MetaVia's DA-1726 Shows Significant Weight Loss Results
- Clinical Trial Results: At the ADA 2026 conference, MetaVia presented new Phase 1 results for DA-1726, achieving up to 9.1% weight loss at the 48 mg dose over 54 days without evidence of a plateau, indicating its potential in obesity treatment.
- Safety and Tolerability: DA-1726 demonstrated good tolerability in the 48 mg cohort, with primarily mild-to-moderate gastrointestinal adverse events and no serious adverse events, highlighting its safety profile for clinical use.
- Combination Therapy Effects: The combination of vanoglipel and resmetirom showed synergistic hepatoprotective and weight-loss effects in mouse models, achieving a 23.6% weight reduction and significantly improving liver fat and inflammation markers, supporting its potential in MASH treatment.
- Metabolic Improvements: When combined with metformin, vanoglipel reduced non-fasting glucose by 28.7% and body weight by 16.3%, demonstrating its advantages in type 2 diabetes treatment and further supporting its potential as a therapeutic combination strategy.
See More
MetaVia Announces Updates on Obesity and Metabolic Therapies
- Management Presentation: MetaVia Inc. will present updates on its novel obesity and metabolic therapies at the Emerging Growth Conference on June 11, 2026, at 3:25 PM ET, featuring insights from CEO Hyung Heon Kim and CFO Marshall H. Woodworth, showcasing the company's innovative advancements in cardiometabolic diseases.
- DA-1726 Clinical Trial: In a Phase 1 multiple ascending dose trial for obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction, functioning as a dual agonist for GLP-1 and GCGR, potentially outperforming selective GLP-1 receptor agonists like semaglutide in weight management.
- Positive Effects of Vanoglipel: As a novel GPR119 agonist, vanoglipel showed positive effects on liver inflammation, lipid metabolism, and glucose metabolism in preclinical studies, reducing hepatic steatosis, inflammation, and fibrosis, while also demonstrating direct hepatic action in a Phase 2a clinical study.
- Virtual Conference Logistics: Attendees can submit questions in advance, and a Q&A session will follow the presentation, while those unable to join live can access an archived webcast on MetaVia's events page, enhancing investor engagement and transparency.
See More
